CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization.

CIRM-Funded Clinical Trials

Photo Credit: UCLA Broad Stem Cell Research Center

Funding Opportunities

Visit our Funding Opportunities page to apply for clinical trial research funding.

Disease Areas	Investigator	Organization	Phase	Trial Status	Target Enrollment
Bladder or Urinary Tract Disorder	James Yoo	Wake Forest University Health Sciences	Phase 1	Not yet recruiting	10
HIV/AIDS Immune Disease	Steven G. Deeks	University of California, San Francisco	Phase 1/2	Recruiting	18
Neurological Disorders Other	Prof. Olivia Kim-McManus	University of California, San Diego	Phase 1/2	Launching	N/A
Cystinosis Kidney Failure	Dr. Stephanie Cherqui	University of California, San Diego	Phase 1/2	Active, not recruiting	6
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease	Dr. Donald B. Kohn	University of California, Los Angeles	Phase 1/2	Recruiting	16
Pediatrics Sickle Cell Disease	Dr. Donald B. Kohn	University of California, Los Angeles	Phase 1	Active, not recruiting	4
Solid Tumors	Dr. Dennis J Slamon	University of California, Los Angeles	Phase 1	Completed	46
Developmental Disorders Spina Bifida	Dr. Diana L. Farmer	University of California, Davis	Phase 1/2	Recruiting	55
Muscle Injury	Peter C Belafsky	University of California, Davis	Phase 1/2	Recruiting	62
Immune Disease	Maria Grazia Roncarolo	Tr1X Inc.	Phase 1	Launching	N/A
Blood Cancer Solid Tumors	Professor Irving L Weissman MD	Stanford University	Phase 1	Completed	88
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID)	Stephen Gottschalk	St. Jude Children’s Research Hospital	Phase 1/2	Suspended	28
Immune Disease Leukocyte Adhesion Deficiency	Kinnari Patel	Rocket Pharmaceuticals, Inc.	Phase 1/2	Completed	9
Danon Disease Pediatrics	Dr. Jonathan Schwartz	Rocket Pharmaceuticals, Inc.	Phase 2	Launching	N/A
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)	Dr. Donald B. Kohn Leslie Meltzer	University of California, Los Angeles Orchard Therapeutics	Phase 2	Completed	10
Developmental Disorders Genetic Disorder Other	Dr. Yael Weiss	Mahzi Therapeutics	Phase 1/2	Launching	N/A
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID)	Dr. Judith A Shizuru Wendy Pang	Stanford University Jasper Therapeutics, Inc.	Phase 1/2	Recruiting	40
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss	Dr Robert Hayes	Immusoft of CA, Inc.	Phase 1	Launching	N/A
Genetic Disorder Metabolic Disorders Other Pediatrics	Dr Robert Hayes	Immusoft of CA, Inc.	Phase 1	Launching	N/A
Immune Disease	Dr. Jonathan Benjamin	ImmPACT-Bio, Inc.	Phase 1/2	Launching	N/A
Neurological Disorders Pediatrics	Gai Ayalon	FOXG1 Research Foundation	Phase 1/2	Launching	N/A
Lupus, Systemic Lupus Erythematosus (SLE)	Dr. Vaneet Sandhu	Fate Therapeutics, Inc.	Phase 1	Launching	N/A
Epilepsy Genetic Disorder	Salvador Rico	Encoded Therapeutics	Phase 2	Launching	N/A
Developmental Disorders Genetic Disorder Other	Dr. Keith Gottlieb	Elpida Therapeutics	Phase 1/2	Launching	N/A
COVID-19 Respiratory Disorders	Prof. John A. Zaia	City of Hope, Beckman Research Institute	Phase 1	Launching	N/A
COVID-19 Respiratory Disorders	William van der Touw	Celularity Inc.	Phase 1/2	Closed	86
Pulmonary Hypertension Vascular Disease	Dr. Michael I Lewis	Cedars-Sinai Medical Center	Phase 1/2	Completed	26
Arthritis Osteoarthritis	Dr. Kristen A Johnson	Calibr	Phase 1	Completed	60